Clarinase Contraindications

Hypersensitivity to the active substances or to any of the excipients listed in Description, or to adrenergic medicinal products.
As Clarinase Repetabs and Clarinase Extended-Release Tablets contains pseudoephedrine, it is also contraindicated in patients who are receiving irreversible monoamine oxidase (MAO) inhibitor therapy or during the 2 weeks following the stopping of such treatment, and in patients with: narrow-angle glaucoma; urinary retention; cardiovascular diseases such as ischaemic heart disease, tachyarrhythmia and severe hypertension; hyperthyroidism; a history of haemorrhagic stroke or with risk factors which could increase the risk of haemorrhagic stroke. This is due to the alpha-mimetic activity of pseudoephedrine, in combination with other vasoconstrictors such as bromocriptine, pergolide, lisuride, cabergoline, ergotamine, dihydroergotamine or any other decongestant medication used as a nasal decongestant, either by oral route or by nasal route (such as phenylpropanolamine, phenylephrine, ephedrine, oxymetazoline, naphazoline).